THE LARGEST COLLECTION OF QUANTITATIVE, VALIDATED IMMUNOASSAYS AVAILABLE
The DiscoveryMAP v. 3.0 service represents the culmination of 15 years of multiplexed immunoassay development and includes:
Cytokines | Chemokines | Metabolic Markers | Hormones | Growth Factors | Tissue Remodeling Proteins | Angiogenesis Markers | Acute Phase Reactants | Cancer Markers | Kidney Damage Markers | CNS Biomarkers
DiscoveryMAP v. 3.0 quantitatively measures over 300 immunoassays, including 60 biomarkers new to Myriad RBM’s menu. It offers insight into disease characterization, progression, and diagnosis as well as a therapeutic compound’s biological activity, efficacy, and safety profile. The unmatched breadth of the DiscoveryMAP v. 3.0 service spans dozens of biological pathways that are relevant to numerous therapy areas including:
Oncology | Immune Response | Metabolism | Cardiovascular | Neurology | Toxicology | Endocrinology | Bone Disease | Gastrointestinal | Endocrinology
Discover New Protein Biomarker Patterns with Myriad RBM’s Discovery Services
Myriad RBM’s discovery services provide a powerful approach for research aimed at identifying reliable predictors of pre-disease states, characterizing pathology, and monitoring therapeutic interventions.
DiscoveryMAP Service Product
View the 60+ new biomarkers
Myriad RBM Quality
DiscoveryMAP samples are tested on an automated platform in Myriad RBM’s CLIA-certified laboratory using proprietary reagents and software. Validation of Myriad RBM’s assays is guided by clinical laboratory standards and is designed to provide accurate and reproducible biomarker measurements. This enables the discovery of patterns made up of multiple biomarkers, many with small, yet reproducibly detectable changes. Multiplexing allows these assays to be performed using less than 1 milliliter of serum or plasma, substantially less than the liters that would be required to test the same content on single-plex platforms, such as ELISA.